Here Is Why Viking Therapeutics (VKTX) is Amongst The Most Affordable Biotech Stocks to Buy

Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the 10 affordable biotech stocks to buy right now.

On June 24, Viking Therapeutics Inc. (NASDAQ:VKTX) disclosed the launch of a Phase 1 Single Ascending Dose (SAD) medical study of VK3019. VK3019 is an experimental Dual Amylin and Calcitonin Receptor Agonist (DACRA), being developed as a possible weight loss therapy.

Pressmaster/Shutterstock.com

The study was initiated after the submission and clearance of the investigational new drug filing of VK3019 with the FDA. The Phase 1 study is a placebo-controlled, randomized, double-blind SAD study in healthy adults with a BMI equal to or greater than 30. The main objectives include assessing the tolerability, safety, and pharmacokinetics of one-time under-the-skin VK3019 doses.

Exploratory analyses include variations in body weight following a one-time dose administration. Besides the Phase 1 trial, Viking is presently performing the Phase 3 VANQUISH studies of under-the-skin VK2735 in overweight patients or patients with obesity.

The company is also working on VK2735’s oral tablet formulation and expects to launch a Phase 3 trial assessing oral VK2735 for overweight and obesity later this year. The company plans to report the findings of the study during the third quarter.

Viking Therapeutics Inc. (NASDAQ:VKTX) specializes in metabolic and endocrine disorder therapies. As a clinical-stage biopharmaceutical company, they direct their research efforts towards small-molecule drugs to cure obesity, fatty liver, and diabetes.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.